Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure

Figures & data

Table 1 Basal characteristics and results

Patient	Gender/age	Imatinib dose (mg)	TTi	Basal PCR	PCR 3 months	MMR 3 months	Cy 6 months*	PCR 6 months	MMR 6 months^†
1	F/27	600	3.47	24.49	6.17	No	PCyR	2.12	No
2	M/36	400	4.8	0.16	0.066	Yes	CCyR	0.046	Yes
3	M/66	400	9.7	49.32	25.82	No	^‡	^‡	^‡
4	F/38	400	5.8	0.56	0.052	Yes	CCyR	0.0085	Yes
5	F/38	400	3.8	12.24	1.568	No	CCyR	0.54	No
6	M/39	800	9.5	6.52	0.063	Yes	CCyR	0.03	Yes
7	M/55	400	2.7	45.59	17.72	No	PCyR	8.73	No
8	M/66	400	3.1	0.29	0.11	No	CCyR	0.052	Yes
9	F/68	600	8.4	12.73	11.18	No	PCyR	3.66	No
10	M/34	600	9.5	4.19	4.68	No	CCyR	0.7	No

PCR, polymerase chain reaction in real time expressed in international scale; MMR, major molecular response; Cy, cytogenetics; PCyR, partial cytogenetic response; CCyR, complete cytogenetic response; TTi, time treatment with imatinib before being randomized into the study (years).

*P < 0.05 compared with basal CCyR.

^†P < 0.05 compared with basal MMR.

^‡Procedure was not performed due to discontinuation of study.

Figure 1 Molecular response to imatinib + nilotinib depicted as ratio of BCR-ABL to ABL transcript, as measured by RT-PCR in 10 CP-CML patients after imatinib failure.